69 related articles for article (PubMed ID: 12205566)
1. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.
Denton M; Kerr K; Mooney L; Keer V; Rajgopal A; Brownlee K; Arundel P; Conway S
Pediatr Pulmonol; 2002 Oct; 34(4):257-61. PubMed ID: 12205566
[TBL] [Abstract][Full Text] [Related]
2. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.
Johansen HK; Moskowitz SM; Ciofu O; Pressler T; Høiby N
J Cyst Fibros; 2008 Sep; 7(5):391-7. PubMed ID: 18358794
[TBL] [Abstract][Full Text] [Related]
3. Drug repositioning: doxazosin attenuates the virulence factors and biofilm formation in Gram-negative bacteria.
Elfaky MA; Elbaramawi SS; Eissa AG; Ibrahim TS; Khafagy ES; Ali MAM; Hegazy WAH
Appl Microbiol Biotechnol; 2023 Jun; 107(11):3763-3778. PubMed ID: 37079062
[TBL] [Abstract][Full Text] [Related]
4. Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.
Martínez-Gallardo MJ; Villicaña C; Yocupicio-Monroy M; Alcaraz-Estrada SL; León-Félix J
Folia Microbiol (Praha); 2023 Feb; 68(1):1-16. PubMed ID: 35931928
[TBL] [Abstract][Full Text] [Related]
5. Repurposing
Almalki AJ; Ibrahim TS; Elhady SS; Darwish KM; Hegazy WAH
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203781
[TBL] [Abstract][Full Text] [Related]
6.
Memar MY; Adibkia K; Farajnia S; Samadi Kafil H; Khalili Y; Azargun R; Ghotaslou R
Iran J Pharm Res; 2021; 20(2):286-296. PubMed ID: 34567162
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of
Izydorczyk C; Waddell B; Edwards BD; Greysson-Wong J; Surette MG; Somayaji R; Rabin HR; Conly JM; Church DL; Parkins MD
Front Microbiol; 2020; 11():475. PubMed ID: 32265892
[No Abstract] [Full Text] [Related]
8. The Essential Role of Hypermutation in Rapid Adaptation to Antibiotic Stress.
Mehta HH; Prater AG; Beabout K; Elworth RAL; Karavis M; Gibbons HS; Shamoo Y
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036684
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.
Parkins MD; Somayaji R; Waters VJ
Clin Microbiol Rev; 2018 Oct; 31(4):. PubMed ID: 30158299
[TBL] [Abstract][Full Text] [Related]
10. Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi.
Qamar S; Shaheen N; Shakoor S; Farooqi J; Jabeen K; Hasan R
Infect Drug Resist; 2017; 10():231-236. PubMed ID: 28814888
[TBL] [Abstract][Full Text] [Related]
11.
Tan JH; Vidaillac C; Yam JKH; Chua SL; Givskov M; Yang L
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461320
[TBL] [Abstract][Full Text] [Related]
12. Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.
Kłodzińska SN; Priemel PA; Rades T; Mørck Nielsen H
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735846
[TBL] [Abstract][Full Text] [Related]
13. Inhaled therapy in cystic fibrosis: agents, devices and regimens.
Agent P; Parrott H
Breathe (Sheff); 2015 Jun; 11(2):110-8. PubMed ID: 26306111
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa high-level resistance to polymyxins and other antimicrobial peptides requires cprA, a gene that is disrupted in the PAO1 strain.
Gutu AD; Rodgers NS; Park J; Moskowitz SM
Antimicrob Agents Chemother; 2015 Sep; 59(9):5377-87. PubMed ID: 26100714
[TBL] [Abstract][Full Text] [Related]
15. Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France.
Sharma P; Gupta SK; Diene SM; Rolain JM
Antimicrob Agents Chemother; 2015 Mar; 59(3):1696-706. PubMed ID: 25583710
[TBL] [Abstract][Full Text] [Related]
16. Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients.
AbdulWahab A; Taj-Aldeen SJ; Ibrahim E; Abdulla SH; Muhammed R; Ahmed I; Abdeen Y; Sadek O; Abu-Madi M
Infect Drug Resist; 2014; 7():309-16. PubMed ID: 25429232
[TBL] [Abstract][Full Text] [Related]
17. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Conole D; Keating GM
Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
[TBL] [Abstract][Full Text] [Related]
18. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.
Gutu AD; Sgambati N; Strasbourger P; Brannon MK; Jacobs MA; Haugen E; Kaul RK; Johansen HK; Høiby N; Moskowitz SM
Antimicrob Agents Chemother; 2013 May; 57(5):2204-15. PubMed ID: 23459479
[TBL] [Abstract][Full Text] [Related]
19. Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.
Ashish A; Shaw M; Winstanley C; Humphreys L; Walshaw MJ
JRSM Short Rep; 2013 Jan; 4(1):1. PubMed ID: 23413403
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Waters V; Zlosnik JE; Yau YC; Speert DP; Aaron SD; Guttman DS
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3341-50. PubMed ID: 22843295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
